Kaur Harpreet, Dhooria Sahajal, Aggarwal Ashutosh N, Gupta Dheeraj, Behera Digambar, Agarwal Ritesh
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Chest. 2015 Sep;148(3):739-745. doi: 10.1378/chest.15-0022.
The optimal concentration of lignocaine to be used during flexible bronchoscopy (FB) remains unknown. This randomized controlled trial compared the efficacy and safety of 1% and 2% lignocaine solution for topical anesthesia during FB.
Consecutive patients were randomized to receive either 1% or 2% lignocaine solution through the bronchoscope by the "spray-as-you-go" technique. The primary outcome of the study was the assessment of cough by the operator and the patient using the visual analog scale (VAS) and pain assessment using the faces pain rating scale. The secondary outcomes included total lignocaine dose, oxygenation status, adverse reactions related to lignocaine, and others.
Five hundred patients were randomized (median age, 51 years; 71% men) 1:1 to either group. The median operator VAS score for cough was significantly higher (25 vs 21, P = .015) in the 1% group; however, the patient VAS score was not significantly different (32 vs 27, P = .065). The pain rating was similar between the two groups. The median cumulative dose of lignocaine was significantly higher in the 2% group (397 mg vs 312 mg, P = .0001; 7.1 mg/kg vs 5.7 mg/kg, P = .0001). About 28% of patients in the 2% group exceeded the maximum recommended dose (> 8.2 mg/kg) of lignocaine. No adverse event related to lignocaine overdose was seen in either group.
One percent lignocaine was found to be as effective as 2% solution for topical anesthesia during FB, albeit at a significantly lower dose as the latter. Thus, 1% lignocaine should be the preferred concentration for topical anesthesia during FB.
ClinicalTrials.gov; No.: NCT01955824; URL: www.clinicaltrials.gov.
在可弯曲支气管镜检查(FB)期间使用的利多卡因最佳浓度仍不清楚。本随机对照试验比较了1%和2%利多卡因溶液用于FB期间局部麻醉的疗效和安全性。
连续的患者通过“边走边喷”技术经支气管镜随机接受1%或2%利多卡因溶液。该研究的主要结局是操作者和患者使用视觉模拟量表(VAS)评估咳嗽情况以及使用面部疼痛评分量表评估疼痛情况。次要结局包括利多卡因总剂量、氧合状态、与利多卡因相关的不良反应等。
500例患者按1:1随机分组(中位年龄51岁;71%为男性)至两组中的任意一组。1%组操作者咳嗽的中位VAS评分显著更高(25比21,P = 0.015);然而,患者VAS评分无显著差异(32比27,P = 0.065)。两组间疼痛评分相似。2%组利多卡因的中位累积剂量显著更高(397 mg比312 mg,P = 0.0001;7.1 mg/kg比5.7 mg/kg,P = 0.0001)。2%组约28%的患者超过了利多卡因的最大推荐剂量(> 8.2 mg/kg)。两组均未观察到与利多卡因过量相关的不良事件。
发现1%利多卡因在FB期间用于局部麻醉与2%溶液效果相同,尽管剂量显著低于后者。因此,1%利多卡因应是FB期间局部麻醉的首选浓度。
ClinicalTrials.gov;编号:NCT01955824;网址:www.clinicaltrials.gov。